{"id":"W2069236338","doi":"10.1111/bjd.13745","title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis","year":2015,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":116,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"U.S. Food and Drug Administration; Astellas Pharma","keywords":"Medicine; Psoriasis; Placebo; Psoriasis Area and Severity Index; Dosing; Adverse effect; Body surface area; Internal medicine; Clinical endpoint; Dermatology Life Quality Index; Clinical trial; Gastroenterology; Randomized controlled trial; Janus kinase; Urology; Cytokine; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00134773,0.0002803851,0.001513604,0.0003578524,0.000149428,0.00004747026,0.0002308602,0.0001882337,0.00002370293],"category_scores_gemma":[0.0003988479,0.0002034551,0.0001545792,0.0002882111,0.000157139,0.0001894675,0.0000931701,0.0003035726,0.00001299818],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007678141,"about_ca_system_score_gemma":0.0002606599,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002325177,"about_ca_topic_score_gemma":0.0003469023,"domain_scores_codex":[0.9964709,0.001446284,0.001233038,0.0003001635,0.0001912948,0.0003582927],"domain_scores_gemma":[0.998062,0.0005264151,0.0005095358,0.0001937659,0.0005852506,0.0001230681],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9746612,0.004865619,0.006321901,0.000008928287,0.001426445,0.0002267753,0.00235266,0.0004188828,0.0003505997,0.00001947589,0.0001843583,0.009163186],"study_design_scores_gemma":[0.9853927,0.002118518,0.006267557,0.0001523742,0.001038673,0.003068229,0.0005187812,0.00002431279,0.001125183,0.00002332134,0.00005020324,0.0002201555],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935749,0.001263852,0.0004792824,0.0002860177,0.0006228173,0.003645418,0.00004894059,0.000009812541,0.00006893949],"genre_scores_gemma":[0.9994739,0.00003752519,0.0001683893,0.00006750356,0.00004885058,0.0001163473,0.00003354308,0.00002235203,0.00003160795],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01073152,"threshold_uncertainty_score":0.829666,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02685597107351539,"score_gpt":0.2808812005526604,"score_spread":0.254025229479145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}